Stock message boards
MNV
Market News Video
MNV MNV Model Portfolios ChartZero
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

ABT November 22nd Options Begin Trading
Monday, March 24, 12:07 PM ET, by Market News Video Staff

Investors in Abbott Laboratories (ABT) saw new options become available today, for the November 22nd ...

VOO, CVX, JPM, PFE: ETF Inflow Alert
Tuesday, March 25, 11:39 AM ET, by Market News Video Staff

Symbols mentioned in this story: VOO, CVX, JPM, PFE Exchange traded funds (ETFs) trade just ...

Notable ETF Inflow Detected - VYM, BMY, UPS, WAG
Tuesday, March 25, 11:39 AM ET, by Market News Video Staff

Symbols mentioned in this story: VYM, BMY, UPS, WAG Exchange traded funds (ETFs) trade just ...

Dr Pepper Snapple Group Inc Becomes #202 Most Shorted S&P 500 Component, Replacing Bristol-Myers Squibb Co.
Wednesday, March 26, 3:31 PM ET, by Market News Video Staff

The most recent short interest data has been released by the NASDAQ for the 03/14/2014 ...

PFE May 9th Options Begin Trading
Thursday, March 27, 11:24 AM ET, by Market News Video Staff

Investors in Pfizer Inc (PFE) saw new options begin trading today, for the May 9th ...

  More articles:  1 2 3 4 5 6 7 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.


Top Six Most Viewed Stories This Week @ Market News Video:
Tuesday Sector Leaders: General Contractors & Builders, Computer PeripheralsTuesday Sector Leaders: General Contractors & Builders, Computer Peripherals
Channel: Market Movers
Related symbols: MHO,BZH,EXTR,KTCC
S&P 500 Analyst Moves: VRTXS&P 500 Analyst Moves: VRTX
Channel: Upgrades/Downgrades
Related symbols: VRTX
Dow Analyst Moves: CSCODow Analyst Moves: CSCO
Channel: Upgrades/Downgrades
Related symbols: CSCO
S&P 500 Analyst Moves: MHKS&P 500 Analyst Moves: MHK
Channel: Upgrades/Downgrades
Related symbols: MHK
Tuesday 4/1 Insider Buying Report: TFM, HEROTuesday 4/1 Insider Buying Report: TFM, HERO
Channel: Insider Buying Report
Related symbols: TFM,HERO
Wednesday 4/2 Insider Buying Report: LUB, EXAWednesday 4/2 Insider Buying Report: LUB, EXA
Channel: Insider Buying Report
Related symbols: LUB,EXA

This Article's Word Cloud:   Abbott   Administration   Definition   Definitions   Drug   Earnings   Elquis   Food   Myers   NYSE   Pfizer   Quadruple   Rate   Relevant   Squibb   Xalkori   approved   atrial   benefit   business   calls   cancer   cell   clinical   companies   company   conducting   disease   drug   embolism   factor   lung   marketing   option   patients   positive   prevention   responsible   risk   said   stroke   systemic   test   that   treatment   trials   weekend   which   with   years
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use & Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  Econonomic News  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Stock Market Definitions
MNV

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2014, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.